Immunohistochemical evaluation for P53 and VEGF (Vascular Endothelial Growth Factor) is not prognostic for long term survival in end stage esophageal adenocarcinoma;Avaliação imunoistoquímica do P53 e VEGF (Fator de Crescimetno Endotelial Vascular) não representa fator prognóstico para sobrevida a longo prazo na fase terminal do adenocarcinoma do esôfago

Revista do Colegio Brasileiro de Cirurgioes

Volumn 36, Issue 1, 2009, Pages 24-34

  Cavazzola, Leandro Totti ^a   Rosa, André Ricardo Pereira da ^a   Schirmer, Carlos Cauduro ^a   Gurski, Richard Ricachenevski ^a   Telles, João Pedro Bueno ^a   Mielke, Fernando ^a   Meurer, Luíse ^a   Edelweiss, Maria Isabel Albano ^a   Kruel, Cleber Dario Pinto ^a  

^a FEDERAL UNIVERSITY OF RIO GRANDE DO SUL   (Brazil)

Author keywords

Esophageal neoplasms; Genes p53; Prognosis; Survivorship; Vascular endothelial growth factor A

Indexed keywords

PROTEIN P53; VASCULOTROPIN A;

ADENOCARCINOMA; ADULT; AGED; ARTICLE; BIOSYNTHESIS; CHEMISTRY; ESOPHAGUS TUMOR; FEMALE; HUMAN; IMMUNOHISTOCHEMISTRY; MALE; METABOLISM; MIDDLE AGED; MORTALITY; PROGNOSIS; PROSPECTIVE STUDY; SURVIVAL RATE; TIME;

ADENOCARCINOMA; ADULT; AGED; ESOPHAGEAL NEOPLASMS; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; PROGNOSIS; PROSPECTIVE STUDIES; SURVIVAL RATE; TIME FACTORS; TUMOR SUPPRESSOR PROTEIN P53; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 67049145025     PISSN: 01006991     EISSN: 18094546     Source Type: Journal    
DOI: 10.1590/S0100-69912009000100007     Document Type: Article

References (96)

1. Blot WJ. Cancer of the esophagus: its causes and changing patterns of occurrence. In: Perry MC, Whippen D, editors. Proceedings of the 33rd American Society of Clinical Oncology - Educational Book; 1997 May 17-20; Denver, USA. USA, American Society of Clinical Oncology; 1997. p. 159-63.
2. Ruol A. Multimodality treatment for non-metastatic cancer of the thoracic esophagus. Dis Esophagus. 1996; 9(1): 39-55.
3. Ribeiro Jr U, Filkelstein SD, Safatle-Ribeiro AV, Landreneau RJ, Clarke MR, Bakker A, Swalsky PA, Gooding WE, Posner MC. p53 sequence analysis predicts treatment response and outcome of patients with esophageal carcinoma. Cancer. 1998; 83(1): 7-18.
4. Fondevila C, Metges JP, Fuster J, Grau JJ, Palacín A, Castells A, Volant A, Pera M. p53 and VEGF expression are independent predictors of tumour recurrence and survival following curative resection of gastric cancer. Br J Cancer. 2004; 90(1): 206-15.
5. Jenkins GJ, Doak SH, Parry JM, D'Souza FR, Griffiths AP, Baxter JN. Genetic pathways involved in the progression of Barrett's metaplasia to adenocarcinoma. Br J Surg. 2002; 89(7): 824-7.
6. Chang F, Syrjänen S, Tervahauta A, Syrjänen K. Tumourigenesis associated with the p53 tumour suppressor gene. Br J Cancer. 1993; 68(4): 653-61.
7. Steele RJ, Thompson AM, Hall PA, Lane DP. The p53 tumor suppressor gene. Br J Surg. 1998; 85(11): 1460-7.
8. Casson AG, Evans SC, Gillis A, Porter GA, Veugelers P, Darnton SJ, Guernsey DL, Hainaut P. Clinical implications of p53 tumor suppressor gene mutation and protein expression in esophageal adenocarcinomas: results of a ten-year prospective study. J Thorac Cardiovasc Surg. 2003; 125(5): 1121-31.
9. Dolan K, Walker SJ, Gosney J, Field JK, Sutton R. TP53 mutations in malignant and premalignant Barrett's esophagus. Dis Esophagus. 2003; 16(2): 83-9.
10. Merola E, Mattioli E, Minimo C, Zuo W, Rabitti C, Cicala M, Caviglia R, Pollice L, Gabbrielli A, Giordano A, Claudio PP. Immunohistochemical evaluation of pRb2/p130, VEGF, EZH2, p53, p16, p21waf-1, p27, and PCNA in Barrett's esophagus. J Cell Physiol. 2006; 207(2): 512-9.
11. Folkman J. Seminars in Medicine of the Beth Israel Hospital, Boston. Clinical applications of research on angiogenesis. N Engl J Med. 1995; 333(26): 1757-63.
12. Ferrara N. Vascular endothelial growth factor. Eur J Cancer. 1996; 32A(14): 2413-22.
13. Gaiso MK. Antiangiogenesis: a new anticancer therapy? Medscape Oncology 1999; 2: 1-5. Available from http://www.medscape.com/viewarticle/408446
14. Coulevard A, Paraf F, Gratio V, Scoazec JY, Hénin D, Degott C, Fléjou JF. Angiogenesis in the neoplastic sequence of Barrett's oesophagus. Correlation with VEGF expression. J Pathol. 2000; 192(1): 14-8.
15. Inoue K, Ozeki Y, Suganuma T, Sugiura Y, Tanaka S. Vascular endothelial growth factor expression in primary esophageal squamous cell carcinoma. Association with angiogenesis and tumor progression. Cancer. 1997; 79(2): 206-13.
16. Kitadai Y, Haruma K, Tokutomi T, Tanaka S, Sumii K, Carvalho M, Kuwabara M, Yoshida K, Hirai T, Kajiyama G, Tahara E. Significance of vessel count and vascular endothelial growth factor in human esophageal carcinomas. Clin Cancer Res. 1998; 4(9): 2195-200.
17. Uchida S, Shimada Y, Watanabe G, Tanaka H, Shibagaki I, Miyahara T, Ishigami S, Imamura M. In oesophageal squamous cell carcinoma vascular endothelial growth factor is associated with p53 mutation, advanced stage and poor prognosis. Br J Cancer. 1998; 77(10): 1704-9.
18. Arii S, Mori A, Uchida S, Fujimoto K, Shimada Y, Inamura M. Implication of vascular endothelial growth factor in the development and metastasis of human cancers. Human Cell. 1999; 12(1): 25-30.
19. Koide N, Nishio A, Hiraguri M, Hanazaki K, Adachi W, Amano J. Coexpression of vascular endothelial growth factor and p53 protein in squamous cell carcinoma of the esophagus. Am J Gastroenterol. 2001; 96(6): 1733-40.
20. Shih CH, Ozawa S, Ando N, Ueda M, Kitajima M. Vascular endothelial growth factor expression predicts outcome and lymph node metastasis in squamous cell carcinoma of the esophagus. Clin Cancer Res. 2000; 6(3): 1161-8.
21. Rosa AR, Schirmer CC, Gurki RR, Meurer L, Edelweiss MI, Kruel CP. Prognostic value of p53 protein expression and vascular endothelial growth factor expression in resected squamous cell carcinoma of the esophagus. Dis Esophagus. 2003; 16(2): 112-8.
22. Kieser A, Weich HA, Brandner G, Marmé D, Kolch W. Mutant p53 potentiates protein kinase C induction of vascular endothelial growth factor expression. Oncogene. 1994; 9(3): 963-9.
23. Mulkhopadhyay D, Tsioskas L, Sukhatame VP. Wild-type p53 and v-Src exert opposing influences on human vascular endothelial growth factor gene expression. Cancer Res. 1995; 55(24): 6161-5.
24. Maeda K, Kang SM, Onoda N, Ogawa M, Sawada T, Nakata B, Kato Y, Chung YS, Sowa M. Expression of p53 and vascular endothelial growth factor associated with tumor angiogenesis and prognosis in gastric cancer. Oncology. 1998; 55(6): 594-9.
25. Maeda K, Kang S, Onoda N, Ogawa M, Kato Y, Sawada T, Chung KH. Vascular endothelial growth factor expression in preoperative biopsy specimens correlates with disease recurrence in patients with early gastric carcinoma. Cancer. 1999; 86(4): 566-71.
26. Rosa AR, Schirmer CC, Gurski RR, Brentano L, Kruel CD. Survival and prognostic factors in patients with resected epidermoid oesophageal carcinoma. Int Surg. 1999; 84(3):193-8.
27. Cavazzola LT, Telles JPB, Pesce G, et al. Delayed cervical esophagogastric anastomosis. In: Pinotti HW, Ceconello I, Felix VN, Oliveira MA, editors. Recent advances in diseases of the esophagus. Bologna: Monduzzi Editore; 2001. p. 579-85.
28. Siewert JR, Stein HJ. Classification of adenocarcinoma of the oesophagogastric junction. Br J Surg. 1998; 85(11): 1457-9.
29. Coggi G, Bosari S, Roncalli M, Graziani D, Bossi P, Viale G, et al. p53 protein accumulation and p53 gene mutation in esophageal carcinoma. A molecular and immunohistochemical study with clinicopathologic correlations. Cancer. 1997; 79(3): 425-32.
30. Kajyiama Y, Hattori K, Tomita N, Amano T, Iwanuma Y, Narumi K, Udagawa H, Tsurumaru M. Histopathologic effects of neoadjuvant therapies for advanced squamous cell carcinoma of the esophagus: multivariate analysis of predictive factors and p53 overexpression. Dis Esophagus. 2002; 15(1): 61-6.
31. Koide N, Nishio A, Kono T, Yazawa K, Igarashi J, Watanabe H, Nimura Y, Hanazaki K, Adachi W, Amano J. Histochemical study of vascular endothelial growth factor in squamous cell carcinoma of the esophagus. Hepatogastroenterology. 1999; 46(26): 952-8.
32. Engel LS, Chow WH, Vaughan TL, Gammon MD, Risch HA, Stanford JL, et al. Population attributable risks of esophageal and gastric cancers. J Natl Cancer Inst. 2003; 95(18):1404-13.
33. Eloubedi MA, Desmond R, Arguedas MR, Reed CE, Wilcox CM. Prognostic factors for the survival of patients with esophageal carcinoma in the U.S.: the importance of tumor length and lymph node status. Cancer. 2002; 95(7): 1434-43.
34. Ikeda M, Natsugoe S, Ueno S, Baba M, Aikou T. Significant hostand tumor-related factors for predicting prognosis in patients with esophageal carcinoma. Ann Surg. 2003; 23(2)8: 197-202.
35. Altorki NK, Oliveria S, Schrump DS. Epidemiology and molecular biology of Barrett's adenocarcinoma. Semin Surg Oncol. 1997; 13(4): 270-80.
36. Slehria S, Sharma P. Barrett's Esophagus. Curr Opin Gastroenterol 2003; 19(4): 387-93. Available at www.medscape.com/viewarticle/457731.
37. Lagergren J, Bergström R, Lindgren A, Nyrén O. Symptomatic gastroesophageal reflux as a risk factor for esophageal adenocarcinoma. N Engl J Med. 1999; 340(11): 825-31.
38. Cameron AJ. Epidemiology of Barrett's esophagus and adenocarcinoma. Dis Esophagus. 2002; 15(2):106-8.
39. Brown LM, Swanson CA, Gridley G, Swanson GM, Schoenberg JB, Greenberg RS, Silverman DT, Pottern LM, Hayes RB, Schwartz AG, et al. Adenocarcinoma of the esophagus: role of obesity and diet. J Natl Cancer Inst. 1995; 87(2): 104-9.
40. Gurski RR, Petters JH, Hagen JA, DeMeester SR, Bremner CG, Chandrasoma PT,. Barrett's esophagus can and does regress after antireflux surgery: a study of prevalence and predictive features. J Am Coll Surg. 2003; 196(5): 706-12; discussion 712-3.
41. Spechler SJ. Clinical practice. Barrett's esophagus. N Engl J Med. 2002; 346(11): 836-42.
42. Watson A. Barrett's oesophagus - 50 years on. Br J Surg. 2000; 87(5): 529-31.
43. Ruol A, Parenti A, Zaninotto G, Merigliano S, Costantini M, Cagol M, et al. Intestinal metaplasia is the probable common precursor of adenocarcinoma in Barrett esophagus and adenocarcinoma of the gastric cardia. Cancer. 2000; 88(11): 2520-8.
44. Blot WJ, Devesa SS, Kneller RW, Fraumeni JF Jr. Rising Incidence of adenocarcinoma of the esophagus and gastric cardia. JAMA. 1991; 265(10): 1287-9.
45. Hansen S, Melby KK, Aase S et al. Role of smoking and Helicobacter pylori infection in aetiology of cardia versus non-cardia gastric cancer [abstract]. Gastroenterology. 2000; 118: A75.
46. Ireland AP, Shibata DK, Chandrasoma P, Lord RVN, Petters JH, DeMeester TR. Clinical significance of p53 mutations in adenocarcinoma of the esophagus and cardia. Ann Surg. 2000; 231(2): 179-87.
47. Wijnhoven BPL, Siersema PD, van Dekken H, Tilanus HW. Adenocarcinomas of the distal oesophagus and gastric cardia are one clinical entity. Rotterdam Oesophageal Tumour Study Group. Br J Surg. 1999; 86(4): 529-35.
48. van Dekken H, Alers J, Riegman PH, Rosenberg C, Tilanus HW, Vissers K. Molecular cytogenetic evaluation of gastric cardia adenocarcinoma and precursor lesions. Am J Pathol. 2001; 158(6): 1961-7.
49. Bruno L, Nesi G, Montinaro F, Carassale G, Lassig R, Boddi V, Bechi P, Cortesini C. Clinicopathologic findings and results of surgical treatment in cardiac adenocarcinoma. J Surg Oncol. 2000; 74(1): 33-5.
50. Taniére P, Martel-Planche G, Maurici D, Lombard-Bohas C, Scoazec JY, Montesano R, Berger F, Hainaut P. Molecular and clinical differences between adenocarcinomas of the esophagus and gastric cardia. Am J Pathol. 2001; 158(1): 33-40.
51. Siewert JR, Feith M, Werner M, Stein HJ, Brennan MF, Wong J. Adenocarcinoma of the esophagogastric junction: results of surgical therapy based on anatomical/topographic classification in 1,002 consecutive patients. Ann Surg. 2000; 232(3): 353-61.
52. Hardiwick RH, Williams GT. Staging of oesophageal adenocarcinoma. Br J Surg. 2002; 89(9): 1076-7.
53. Siewert JR, Stein HJ, Feith M, Bruecher BLDM, Bartels H, Fink U. Histologic tumor type is an independent prognostic parameter in esophageal cancer: lessons from more than 1,000 consecutive resections at a single center in the Western world. Ann Surg. 2001; 234(3): 360-7; discusiion 368-9.
54. Siewert JR, Stein HJ, Sendler A, et al. Esophageal cancer: clinical management. In: Kelsen DA, ed. Principles and practice of gastrointestinal oncology. Philadelphia: Lippincot Williams & Willliams; 2001. 976 p.
55. Lerut T, DeDeyn P, Coosemans W, Van Raemdonck D, Scheys I, LeSaffre E. Surgical strategies in esophageal carcinoma with emphasis on radical lymphadenectomy. Ann Surg. 1992; 216(5): 583-90.
56. Hagen JA, Peters JH, DeMeester TR. Superiority of extended en bloc esophagogastrectomy for carcinoma of the lower esophagus and cardia. J Thorac Cardiovasc Surg. 1993; 106(5): 850-8; discussion 858-9.
57. Alexandrou A, Davis PA, Law S, Murthy S, Whooley BP, Wong J. Squamous cell carcinoma and adenocarcinoma of the lower third of the esophagus and gastric cardia: similarities and differences. Dis Esophagus. 2002; 15(4): 290-5.
58. Bollschweiler E, Schröder W, Hölscher AH, Siewert JR. Preoperative risk analysis in patients with adenocarcinoma or squamous cell carcinoma of the esophagus. Br J Surg. 2000; 87(8): 1106-10.
59. Shinohara M, Aoki T, Sato S, Takagi Y, Osaka Y, Koyanagi Y, Hatooka S, Shinoda M. Cell cycle-regulated factors in esophageal cancer. Dis Esophagus. 2002; 15(2):149-54.
60. Audrézet MP, Robaszkiewicz M, Mercier B, Nousbaum JB, Hardy E, Bail JP, Volant A, Lozac'h P, Gouérou H, Férec C. Molecular analysis of the TP53 gene in Barrett's adenocarcinoma. Hum Mutat. 1996; 7(2): 109-13.
61. waf1/cip1 and p53 tumor suppressor in dysplastic progression and adenocarcinoma in Barrett esophagus. Cancer. 1999; 86(5): 756-63.
62. Kobayashi S, Koide Y, Endo M, Isono K, Ochiai T. The p53 gene mutation is of prognostic value in esophageal squamous cell carcinoma patients in unified stages of curability. Am J Surg. 1999; 177(6): 497-502.
63. Fagundes RB, Mello CR, Tollens P, Pütten AC, Wagner MB, Moreira LF, Barros SG. p53 protein in esophageal mucosa of individuals at high risk of squamous cell carcinoma of the esophagus. Dis Esophagus. 2001; 14(3-4):185-90.
64. Ikeguchi M, Saito H, Katano K, Tsujitani S, Maeta M, Kaibara N. Clinicopathologic significance of the expression of mutated p53 protein and the proliferative activity of cancer cells in patients with esophageal squamous cell carcinoma. J Am Coll Surg. 1997; 185(4): 398-403.
65. Kanamoto A, Kato H, Tachimori Y, Watanabe H, Nakanishi Y, Kondo H, Yamaguchi H, Gotoda T, Muro K, Matsumura Y. No prognostic significance of p53 expression in esophageal squamous cell carcinoma. J Surg Oncol. 1999; 72(2): 94-8.
66. Sarbia M, Vereet PR, Röher HD. Relevant prognostic biological and morphological factors in esophageal cancer. In: Perachia A, Rosati R, Bonavina L, Fumagalli U, Bona S, Chella B, editors. Recent advances in diseases of the esophagus. Bologna: Monduzzi Editore; 1996. p.15-8.
67. Brown JM, Wouters BG. Apoptosis, p53, and tumor cell sensitivity to anticancer agents. Cancer Res. 1999; 59(7): 1391-9.
68. Mathew R, Arora S, Khanna R, Mathur M, Shukla NK, Ralhan R. Alterations in p53 and pRb pathways and their prognostic significance in oesophageal cancer. Eur J Cancer. 2002; 38(6): 832-41.
69. Vijeyasingam R, Darnton SJ, Jenner K, Allen CA, Billingham C, Matthews HR. Expression p53 protein in oesophageal carcinoma: clinicopathological correlation and prognostic significance. Br J Surg. 1994; 81(11): 1623-6.
70. Patel DD, Bhatavdekar JM, Chikhlikar PR, Patel YV, Shah NG, Ghosh N, Suthar TP, Balar DB. Clinical significance of p53, nm23, and bcl-2 in T3-4N1M0 oesophageal carcinoma: an immunohistochemical approach. J Surg Oncol. 1997; 65(2): 111-6.
71. Casson AG, Tammemagi M, Eskandarian S, Redston M, McLaughlin J, Ozcelik H. p53 alterations in oesophageal cancer: association with clinicopathological features, risk factors, and survival. Mol Pathol. 1998; 51(2): 71-9.
72. Younes M, Ertan A, Lechago J. p53 protein and malignant progression in Barrett's metaplasia (Barrett's esophagus). Am J Gastroenterol. 2003; 98(5): 1200-1; author reply 1201.
73. Wu TT, Watanabe T, Heitmiller R, Zahurak M, Forastiere AA, Hamilton SR. Genetic alterations in Barrett esophagus and adenocarcinomas of the esophagus and esophagogastric junction region. Am J Pathol. 1998; 153(1): 287-94.
74. Wijnhoven BP, Tilanus HW, Dinjens WN. Molecular biology of Barrett's adenocarcinoma. Ann Surg. 2001; 233(3): 322-37.
75. Adulaimi D, Jankowki J. Barrett's esophagus: an overview of the molecular biology. Dis Esophagus. 1999; 12(3): 177-80.
76. Ellis LM, Fidler IJ. Angiogenesis and metastasis. Eur J Cancer. 1996; 32A(14):2451-60.
77. Folkman J. What is the evidence that tumors are angiogenesis dependent? J Natl Cancer Inst. 1990; 82(1):4-6.
78. Folkman J. How is blood vessel growth regulated in normal and neoplastic tissue? G.H.A. Clowes memorial Award lecture. Cancer Res. 1986; 46(2):467-73.
79. Poon RTP, Fan ST, Wong J. Clinical significance of angiogenesis in gastrointestinal cancers - a target of novel prognostic and therapeutic approaches. Ann Surg. 2003; 238(1): 9-28.
80. Nicosia R. What is the role of vascular endothelial growth factor-related molecules in tumor angiogenesis. Am J Pathol. 1998; 153(1): 11-6.
81. Thomas KA. Vascular endothelial growth factor, a potent and selective angiogenic agent. J Biol Chem. 1996; 271(2): 603-6.
82. Vermeulen PB, Gasparini G, Fox SB, Toi M, Martin L, McCulloch P, Pezzella F, Viale G, Weidner N, Harris AL, Dirix LY. Quantification of angiogenesis in solid human tumors: an international consensus on the methodology and criteria of evaluation. Eur J Cancer. 1996; 32A(14): 2474-84.
83. Shweiki D, Itin A, Soffer D, Keshet E. Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis. Nature. 1992; 359(6398): 843-5.
84. Shimada H, Takeda A, Nabeya Y, Okazumi SI, Matsubara H, Funami Y, et al. Clinical significance of serum vascular endothelial growth factor in esophageal squamous cell carcinoma. Cancer. 2001; 92(3): 663-9.
85. Wilson KT. Angiogenic markers, neovascularization and malignant deformation of Barrett's esophagus. Dis Esophagus. 2002; 15(1): 16-21.
86. Rak J, Yu JL. Oncogenes and tumor angiogenesis: the question of vascular "supply" and vascular "demand". Semin Cancer Biol. 2004; 14(2): 93-104.
87. DeMeester SR. Lymph node involvement in esophageal adenocarcinoma: if you see one, have you seen them all? J Thorac Cardiovasc Surg. 2003; 126(4): 947-9.
88. Lerut T, Coosemans W, Decker G, De Leyn P, Ectors N, Fieuws S, et al. Extracapsular lymph node involvement is a negative prognostic factor in T3 adenocarcinoma of the distal esophagus and gastroesophageal junction. J Thorac Cardiovasc Surg. 2003; 126(4): 1121-7.
89. Sato F, Shimada Y, Watanabe G, Uchida S, Makino T, Imamura M. Expression of vascular endothelial growth factor, matrix metalloproteinase-9 and E-cadherin in the process of lymph node metastasis in oesophageal cancer. Br J Cancer. 1999; 80(9):1366-72.
90. Torres C, Wang H, Tuner SJ, Shahsafaei A, Odze RD. Prognostic significance and effect of chemoradiotherapy on microvessel density in esophageal Barrett's adenocarcinoma and squamous cell carcinoma. Human Pathol. 1999; 30(7): 753-8.
91. McDonnell CO, Bouchier-Hayes DJ, Toomey D, Foley D, Kay EW, Leen E, Walsh TN. Effect of neoadjuvant chemoradiotherapy on angiogenesis in oesophageal cancer. Br J Surg. 2003; 90(11): 1373-8.
92. McDonnell CO, Harvey JH, Bouchier-Hayes DJ, Walsh NJ. Effect of multimodality therapy on circulating vascular endothelial growth factor levels in patients with esophageal cancer. Br J Surg. 2001; 88(8): 1105-9.
93. Han U, Can OI, Han S, Kayhan B, Onal BU. Expressions of p53, VEGF C, p21: could they be used in preoperative evaluation of lymph node metastasis of esophageal squamous cell carcinoma? Dis Esophagus. 2007; 20(5): 379-85.
94. Ahn MJ, Jang SJ, Park YW, Choi JH, Oh HS, Lee CB, Paik HK, Park CK. Clinical prognostic values of vascular endothelial growth factor, microvessel density, and p53 expression in esophageal carcinomas. J Korean Med Sci. 2002; 17(2): 201-7.
95. Merola E, Mattioli E, Minimo C, Zuo W, Rabitti C, Cicala M, Caviglia R, Pollice L, Gabbrielli A, Giordano A, Claudio PP. Immunohistochemical evaluation of pRb2/p130, VEGF, EZH2, p53, p16, p21waf-1, p27, and PCNA in Barrett's esophagus. J Cell Physiol. 2006; 207(2):512-9.
96. Montero E, Abreu C, Tonino P. Relationship between VEGF and p53 expression and tumor cell proliferation in human gastrointestinal carcinomas. J Cancer Res Clin Oncol. 2008; 134(2):193-201. Epub 2007 Jul 17.